1. Home
  2. ASC vs NGNE Comparison

ASC vs NGNE Comparison

Compare ASC & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ardmore Shipping Corporation

ASC

Ardmore Shipping Corporation

HOLD

Current Price

$17.31

Market Cap

751.7M

ML Signal

HOLD

Logo Neurogene Inc.

NGNE

Neurogene Inc.

HOLD

Current Price

$36.89

Market Cap

744.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ASC
NGNE
Founded
2010
2003
Country
Bermuda
United States
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
751.7M
744.9M
IPO Year
2013
2014

Fundamental Metrics

Financial Performance
Metric
ASC
NGNE
Price
$17.31
$36.89
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
7
Target Price
$17.00
$63.57
AVG Volume (30 Days)
592.9K
194.3K
Earning Date
05-07-2026
05-08-2026
Dividend Yield
1.74%
N/A
EPS Growth
N/A
0.93
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$16.60
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.31
$15.93
52 Week High
$20.03
$43.66

Technical Indicators

Market Signals
Indicator
ASC
NGNE
Relative Strength Index (RSI) 47.83 51.43
Support Level $15.04 $18.24
Resistance Level $17.81 $43.66
Average True Range (ATR) 0.62 2.66
MACD -0.09 0.02
Stochastic Oscillator 37.12 58.04

Price Performance

Historical Comparison
ASC
NGNE

About ASC Ardmore Shipping Corporation

Ardmore Shipping Corp provides seaborne transportation of petroleum products and chemicals world-wide to oil majors, national oil companies, oil and chemical traders, and chemical companies, with its modern, fuel-efficient fleet of mid-size product and chemical tankers. The company markets its services directly to its customers and commercial pool operators and charters its vessels to them through a combination of spot, commercial pooling, and time-charter arrangements. The majority of its revenue is generated from spot voyages, which typically last less than three months.

About NGNE Neurogene Inc.

Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.

Share on Social Networks: